Innovative therapeutics

Investors

Analyst Coverage

BioMarin Pharmaceutical Inc. is covered by the following analysts.

Firm Analyst
Bank of America Merrill Lynch Ying Huang
Barclays Geoffrey Meacham
Bernstein Vincent Chen
BMO Capital Markets M. Ian Somaiya
Citi Robyn Karnauskas
Cowen & Company Philip Nadeau
Credit Suisse Alethia Young
Deustche Bank Andrew Peters
Evercore ISI Joshua Schimmer
Goldman Sachs Salveen Richter
Jefferies Eun Yang
JP Morgan Cory Kasimov
Leerink Swann Joseph P. Schwartz
Morgan Stanley Matthew Harrison
Morningstar Karen Andersen
Nomura Christopher Marai
Piper Jaffray Christopher Raymond
Raymond James Laura Chico
Robert W. Baird Michael Ulz
RBC Kennen MacKay
Stifel Nicolaus Stephen Willey
SunTrust Edward Nash
Wedbush Morgan Liana Moussatos
William Blair & Company Tim Lugo

 

Please note that any opinions, estimates or forecasts regarding BioMarin Pharmaceutical Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of BioMarin Pharmaceutical Inc. or its management. BioMarin Pharmaceutical Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.


BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information